Delisting riskPopularity #4,702
Burning Rock Biotech (ADR) (BNR)
NGS oncology testing, hospital workflows, and biopharma development services.
$14.77
vs last close−1.68 (−10.21%)
In millions of USD, except per-share figures · converted from CNY at the latest rate
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 19 | 18 | 19 | 20 | 19 | 19 | 20 | 22 | 20 | 19 | 16 | 20 |
| Cost of revenue | 6 | 6 | 6 | 6 | 5 | 5 | 5 | 6 | 5 | 4 | 4 | 6 |
| Gross profit | 13 | 12 | 13 | 14 | 14 | 13 | 15 | 16 | 15 | 15 | 12 | 15 |
| 40 | 36 | 32 | 31 | 19 | 26 | 17 | 18 | 17 | 17 | 14 | 17 | |
| Research & development | 12 | 11 | 10 | 10 | 7 | 8 | 6 | 7 | 6 | 5 | 4 | 5 |
| 27 | 26 | 22 | 21 | 12 | 13 | 11 | 10 | 11 | 11 | 10 | 13 | |
| Selling & marketing | 9 | 7 | 7 | 7 | 7 | 7 | 6 | 6 | 6 | 7 | 6 | 7 |
| General & administrative | 18 | 18 | 15 | 14 | 5 | 6 | 5 | 5 | 5 | 5 | 4 | 6 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | −27 | −25 | −19 | −17 | −6 | −12 | −2 | −2 | −2 | −2 | −3 | −3 |
| 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | — | |
| Interest income | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | −3 | −1 | −1 | 0 | −5 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | −26 | −24 | −18 | −16 | −5 | −11 | −2 | −1 | −2 | −2 | −3 | −3 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | −26 | −24 | −18 | −16 | −5 | −12 | −2 | −1 | −3 | −2 | −3 | −3 |
| Net income | −26 | −24 | −18 | −16 | −5 | −12 | −2 | −1 | −3 | −2 | −3 | −3 |
| EPS, basic | −$25.52 | −$23.64 | −$17.68 | −$15.71 | −$5.16 | −$11.74 | −$1.87 | −$1.34 | −$2.33 | −$2.19 | −$2.54 | −$2.54 |
| EPS, diluted | −$25.52 | −$23.64 | −$17.68 | −$15.71 | −$5.16 | −$11.74 | −$1.87 | −$1.34 | −$2.33 | −$2.19 | −$2.54 | −$2.54 |
| Weighted average shares, basic | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Weighted average shares, diluted | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | −22 | −16 | −13 | −16 | 0 | −5 | −2 | 1 | −2 | 1 | −3 | −2 |
| Depreciation & amortization | 5 | 6 | 5 | 0 | 5 | 2 | 0 | 2 | 0 | 3 | 0 | 0 |
| EBIT | −27 | −22 | −18 | −16 | −5 | −7 | −2 | −1 | −2 | −2 | −3 | −3 |